

Itamar Raz

List of Publications by Year in Descending Order

Source: <https://exaly.com/author-pdf/7280818/itamar-raz-publications-by-year.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

156
papers

12,869
citations

41
h-index

113
g-index

171
ext. papers

16,326
ext. citations

10.9
avg. IF

6.36
L-index

#	Paper	IF	Citations
156	Effect of Dapagliflozin on Hematocrit in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From DECLARE-TIMI 58.. <i>Diabetes Care</i> , 2022 , 45, e27-e29	14.6	1
155	Letter Regarding Normal Albuminuria in Patients With Autopsy-Proven Advanced Diabetic Nephropathy.. <i>Kidney International Reports</i> , 2022 , 7, 662	4.1	1
154	Cytochrome c Oxidase Activity as a Metabolic Regulator in Pancreatic Beta-Cells.. <i>Cells</i> , 2022 , 11,	7.9	2
153	Comment on Oosterwijk et al. High-Normal Protein Intake Is Not Associated With Faster Renal Function Deterioration in Patients With Type 2 Diabetes: A Prospective Analysis in the DIALECT Cohort. <i>Diabetes Care</i> 2022;45:35-41.. <i>Diabetes Care</i> , 2022 , 45, e67-e68	14.6	1
152	Sodium-glucose Cotransporter 2 Inhibitors and Risk of Hyperkalemia in People with Type 2 diabetes: A Meta-analysis of Individual Participant Data from Randomized Controlled Trials.. <i>Circulation</i> , 2022 ,	16.7	8
151	The relationship between inpatient hyperglycaemia and mortality is modified by baseline glycaemic status. <i>Diabetes/Metabolism Research and Reviews</i> , 2021 , 37, e3420	7.5	0
150	Assessing reproducibility and utility of clustering of patients with type 2 diabetes and established CV disease (SAVOR -TIMI 53 trial). <i>PLoS ONE</i> , 2021 , 16, e0259372	3.7	0
149	Five years into the Israeli National Diabetes Program - are we on the right track?. <i>Diabetes/Metabolism Research and Reviews</i> , 2021 , 37, e3421	7.5	0
148	Relationship between baseline cardiac biomarkers and cardiovascular death or hospitalization for heart failure with and without sodium-glucose co-transporter 2 inhibitor therapy in DECLARE-TIMI 58. <i>European Journal of Heart Failure</i> , 2021 , 23, 1026-1036	12.3	16
147	Haemoglobin A1c is a predictor of COVID-19 severity in patients with diabetes. <i>Diabetes/Metabolism Research and Reviews</i> , 2021 , 37, e3398	7.5	22
146	Cardiovascular, Renal, and Metabolic Outcomes of Dapagliflozin Versus Placebo in a Primary Cardiovascular Prevention Cohort: Analyses From DECLARE-TIMI 58. <i>Diabetes Care</i> , 2021 , 44, 1159-1167	14.6	7
145	From glucose lowering agents to disease/diabetes modifying drugs: a "SIMPLE" approach for the treatment of type 2 diabetes. <i>Cardiovascular Diabetology</i> , 2021 , 20, 92	8.7	8
144	Preinfection glycaemic control and disease severity among patients with type 2 diabetes and COVID-19: A retrospective, cohort study. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 1995-2000	6.7	4
143	Adolescent Thyroid Disorders and Risk for Type 2 Diabetes in Young Adulthood. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, e3426-e3435	5.6	4
142	Effect of a primary-care-team focused diabetes educational program project on diabetes care quality indicators in a large health maintenance organization. <i>Diabetes Research and Clinical Practice</i> , 2021 , 177, 108896	7.4	2
141	Asthma in Youth and Early-onset Type 2 Diabetes: A Nationwide Study of 1.72 Million Israeli Adolescents. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, e5043-e5053	5.6	0
140	The Effect of Dapagliflozin on Albuminuria in DECLARE-TIMI 58. <i>Diabetes Care</i> , 2021 , 44, 1805-1815	14.6	10

139	Adolescent Hypertension and Risk for Early-Onset Type 2 Diabetes: A Nationwide Study of 1.9 Million Israeli Adolescents. <i>Diabetes Care</i> , 2021 , 44, e6-e8	14.6	4
138	NAFLD in type 2 diabetes mellitus: Still many challenging questions. <i>Diabetes/Metabolism Research and Reviews</i> , 2021 , 37, e3386	7.5	5
137	Clinical Application of a Novel Genetic Risk Score for Ischemic Stroke in Patients With Cardiometabolic Disease. <i>Circulation</i> , 2021 , 143, 470-478	16.7	13
136	Management of patients with diabetes and obesity in the COVID-19 era: Experiences and learnings from South and East Europe, the Middle East, and Africa. <i>Diabetes Research and Clinical Practice</i> , 2021 , 172, 108617	7.4	12
135	Adolescent Nonalcoholic Fatty Liver Disease and Type 2 Diabetes in Young Adulthood. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, e34-e44	5.6	5
134	Tackling obesity during the COVID-19 pandemic. <i>Diabetes/Metabolism Research and Reviews</i> , 2021 , 37, e3393	7.5	2
133	Cardiorenal outcomes with dapagliflozin by baseline glucose-lowering agents: Post hoc analyses from DECLARE-TIMI 58. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 29-38	6.7	11
132	Stuttering and Incident Type 2 Diabetes: A Population-Based Study of 2.2 Million Adolescents. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2021 , 106, 978-987	5.6	2
131	Changes in Albuminuria Predict Cardiovascular and Renal Outcomes in Type 2 Diabetes: A Post Hoc Analysis of the LEADER Trial. <i>Diabetes Care</i> , 2021 , 44, 1020-1026	14.6	7
130	The efficacy and safety of dapagliflozin in women and men with type 2 diabetes mellitus. <i>Diabetologia</i> , 2021 , 64, 1226-1234	10.3	4
129	Genetic Risk Score to Identify Risk of Venous Thromboembolism in Patients With Cardiometabolic Disease. <i>Circulation Genomic and Precision Medicine</i> , 2021 , 14, e003006	5.2	1
128	Protective effects of SGLT-2 inhibitors across the cardiorenal continuum: two faces of the same coin. <i>European Journal of Preventive Cardiology</i> , 2021 ,	3.9	7
127	Machine learning based study of longitudinal HbA1c trends and their association with all-cause mortality: Analyses from a National Diabetes Registry. <i>Diabetes/Metabolism Research and Reviews</i> , 2021 , e3485	7.5	1
126	Effect of Dapagliflozin on Cardiovascular Outcomes According to Baseline Kidney Function and Albuminuria Status in Patients With Type 2 Diabetes: A Prespecified Secondary Analysis of a Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2021 , 6, 801-810	16.2	4
125	Serum from type 2 diabetes patients consuming a three-meal diet resets circadian rhythms in cultured hepatocytes. <i>Diabetes Research and Clinical Practice</i> , 2021 , 178, 108941	7.4	
124	A Biomarker-Based Score for Risk of Hospitalization for Heart Failure in Patients With Diabetes. <i>Diabetes Care</i> , 2021 , 44, 2573-2581	14.6	0
123	Management of diabetic neuropathy. <i>Metabolism: Clinical and Experimental</i> , 2021 , 123, 154867	12.7	3
122	Adolescent cognitive function and incident early-onset type 2 diabetes. <i>EClinicalMedicine</i> , 2021 , 41, 101138	13.3	1

121	Adolescent BMI and early-onset type 2 diabetes among Ethiopian immigrants and their descendants: a nationwide study. <i>Cardiovascular Diabetology</i> , 2020 , 19, 168	8.7	4
120	Positioning sulphonylureas in a modern treatment algorithm for patients with type 2 diabetes: Expert opinion from a European consensus panel. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 1705-1713	6.7	8
119	Cardiovascular and renal outcomes by baseline albuminuria status and renal function: Results from the LEADER randomized trial. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 2077-2088	6.7	3
118	Digital Diabetes Care System Observations from a Pilot Evaluation Study in Vietnam. <i>International Journal of Environmental Research and Public Health</i> , 2020 , 17,	4.6	1
117	Cardiovascular and renal benefits of dapagliflozin in patients with short and long-standing type 2 diabetes: Analysis from the DECLARE-TIMI 58 trial. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 1122-1131	6.7	13
116	Prediction of progression from pre-diabetes to diabetes: Development and validation of a machine learning model. <i>Diabetes/Metabolism Research and Reviews</i> , 2020 , 36, e3252	7.5	19
115	Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial. <i>Circulation</i> , 2020 , 141, 1227-1234	16.7	97
114	Safety of dapagliflozin in a broad population of patients with type 2 diabetes: Analyses from the DECLARE-TIMI 58 study. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 1357-1368	6.7	13
113	Abstract 15701: Relationship Between Cardiac Biomarkers and Major Adverse Cardiovascular Events in DECLARE-TIMI 58. <i>Circulation</i> , 2020 , 142,	16.7	1
112	Abstract 16139: A Targeted Proteomic Approach to Identify Circulating Biomarkers of Heart Failure Risk in Patients With Type 2 Diabetes Mellitus in DECLARE-TIMI 58. <i>Circulation</i> , 2020 , 142,	16.7	1
111	Childhood Pancreatitis and Risk for Incident Diabetes in Adulthood. <i>Diabetes Care</i> , 2020 , 43, 145-151	14.6	11
110	SGLT2 inhibitors for primary prevention of cardiovascular events. <i>Journal of Diabetes</i> , 2020 , 12, 5-7	3.8	4
109	Efficacy and Safety of Dapagliflozin in the Elderly: Analysis From the DECLARE-TIMI 58 Study. <i>Diabetes Care</i> , 2020 , 43, 468-475	14.6	33
108	Insulin Therapy: Future Perspectives. <i>American Journal of Therapeutics</i> , 2020 , 27, e121-e132	1	16
107	Dapagliflozin and Cardiac, Kidney, and Limb Outcomes in Patients With and Without Peripheral Artery Disease in DECLARE-TIMI 58. <i>Circulation</i> , 2020 , 142, 734-747	16.7	16
106	Response by Zelniker et al to Letter Regarding Article, "Effect of Dapagliflozin on Atrial Fibrillation in Patients With Type 2 Diabetes Mellitus: Insights From the DECLARE-TIMI 58 Trial". <i>Circulation</i> , 2020 , 142, e129-e130	16.7	4
105	Adolescent Obesity and Early-Onset Type 2 Diabetes. <i>Diabetes Care</i> , 2020 , 43, 1487-1495	14.6	36
104	Safety of Liraglutide in Type 2 Diabetes and Chronic Kidney Disease. <i>Clinical Journal of the American Society of Nephrology: CJASN</i> , 2020 , 15, 465-473	6.9	15

103	Heart Failure Risk Stratification and Efficacy of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Type 2 Diabetes Mellitus. <i>Circulation</i> , 2019 , 140, 1569-1577	16.7	57
102	SGLT-2 inhibitors for people with type 2 diabetes - AuthorsReply. <i>Lancet, The</i> , 2019 , 394, 560-561	4.0	4
101	Reduction in Glycated Hemoglobin and Daily Insulin Dose Alongside Circadian Clock Upregulation in Patients With Type 2 Diabetes Consuming a Three-Meal Diet: A Randomized Clinical Trial. <i>Diabetes Care</i> , 2019 , 42, 2171-2180	14.6	31
100	Effects of dapagliflozin on development and progression of kidney disease in patients with type 2 diabetes: an analysis from the DECLARE-TIMI 58 randomised trial. <i>Lancet Diabetes and Endocrinology, the</i> , 2019 , 7, 606-617	18.1	304
99	Response by Mann et al to Letter Regarding Article, "Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease: Results From the LEADER Trial". <i>Circulation</i> , 2019 , 139, e1017-e1018	16.7	1
98	Effect of Injection Site Cooling and Warming on Insulin Glargine Pharmacokinetics and Pharmacodynamics. <i>Journal of Diabetes Science and Technology</i> , 2019 , 13, 1123-1128	4.1	1
97	Effect of Flash Glucose Monitoring Technology on Glycemic Control and Treatment Satisfaction in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2019 , 42, 1178-1184	14.6	65
96	Cardiac and Inflammatory Biomarkers Are Associated with Worsening Renal Outcomes in Patients with Type 2 Diabetes Mellitus: Observations from SAVOR-TIMI 53. <i>Clinical Chemistry</i> , 2019 , 65, 781-790	5.5	7
95	Dapagliflozin and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus and Previous Myocardial Infarction. <i>Circulation</i> , 2019 , 139, 2516-2527	16.7	142
94	Effect of Dapagliflozin on Heart Failure and Mortality in Type 2 Diabetes Mellitus. <i>Circulation</i> , 2019 , 139, 2528-2536	16.7	283
93	An evaluation of the efficacy and safety of Tofogliflozin for the treatment of type II diabetes. <i>Expert Opinion on Pharmacotherapy</i> , 2019 , 20, 781-790	4	4
92	Metformin Use and Clinical Outcomes Among Patients With Diabetes Mellitus With or Without Heart Failure or Kidney Dysfunction: Observations From the SAVOR-TIMI 53 Trial. <i>Circulation</i> , 2019 , 140, 1004-1014	16.7	40
91	Comparison of the Effects of Glucagon-Like Peptide Receptor Agonists and Sodium-Glucose Cotransporter 2 Inhibitors for Prevention of Major Adverse Cardiovascular and Renal Outcomes in Type 2 Diabetes Mellitus. <i>Circulation</i> , 2019 , 139, 2022-2031	16.7	345
90	Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes. <i>New England Journal of Medicine</i> , 2019 , 380, 347-357	59.2	2455
89	SGLT2 inhibitors for primary and secondary prevention of cardiovascular and renal outcomes in type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials. <i>Lancet, The</i> , 2019 , 393, 31-39	4.0	1300
88	Validity of diagnostic codes and estimation of prevalence of diabetic foot ulcers using a large electronic medical record database. <i>Diabetes/Metabolism Research and Reviews</i> , 2019 , 35, e3094	7.5	2
87	Incidence and Risk Factors for Mortality Following Bariatric Surgery: a Nationwide Registry Study. <i>Obesity Surgery</i> , 2018 , 28, 2661-2669	3.7	20
86	The design and rationale for the Dapagliflozin Effect on Cardiovascular Events (DECLARE)-TIMI 58 Trial. <i>American Heart Journal</i> , 2018 , 200, 83-89	4.9	89

85	Calculating individualized glycaemic targets using an algorithm based on expert worldwide diabetologists: Implications in real-life clinical practice. <i>Diabetes/Metabolism Research and Reviews</i> , 2018 , 34, e2976	7.5	3
84	Cardiovascular Outcomes Trials in Type 2 Diabetes: Where Do We Go From Here? Reflections From a EditorsSExpert Forum. <i>Diabetes Care</i> , 2018 , 41, 14-31	14.6	263
83	DECLARE-TIMI 58: ParticipantsSbaseline characteristics. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 1107-1108	7.1	1108
82	The Berlin Declaration: A call to action to improve early actions related to type 2 diabetes. How can specialist care help?. <i>Diabetes Research and Clinical Practice</i> , 2018 , 139, 392-399	7.4	12
81	Digital health technology and diabetes management. <i>Journal of Diabetes</i> , 2018 , 10, 10-17	3.8	40
80	Glycemic Targets and Prevention of Chronic Complications. <i>Endocrinology</i> , 2018 , 1-31	0.1	
79	The Berlin Declaration: A call to improve early actions related to type 2 diabetes. Why is primary care important?. <i>Primary Care Diabetes</i> , 2018 , 12, 383-392	2.4	6
78	Glycemic Targets and Prevention of Chronic Complications. <i>Endocrinology</i> , 2018 , 421-450	0.1	
77	Risk Assessment in Patients With Diabetes With the TIMI Risk Score for Atherothrombotic Disease. <i>Diabetes Care</i> , 2018 , 41, 577-585	14.6	16
76	Patient clusters based on HbA1c trajectories: A step toward individualized medicine in type 2 diabetes. <i>PLoS ONE</i> , 2018 , 13, e0207096	3.7	16
75	Comparison of HBA1c Goals Proposed by an Algorithm To Those Set By Different Members of Healthcare Teams Within the Dartmouth Hitchcock Health System. <i>Endocrine Practice</i> , 2018 , 24, 705-709 ³⁻²	3.2	2
74	Effects of Liraglutide Versus Placebo on Cardiovascular Events in Patients With Type 2 Diabetes Mellitus and Chronic Kidney Disease. <i>Circulation</i> , 2018 , 138, 2908-2918	16.7	48
73	Cardiovascular benefit in the limelight: shifting type 2 diabetes treatment paradigm towards early combination therapy in patients with overt cardiovascular disease. <i>Cardiovascular Diabetology</i> , 2018 , 17, 117	8.7	4
72	Cardiovascular Outcomes According to Urinary Albumin and Kidney Disease in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial. <i>JAMA Cardiology</i> , 2018 , 3, 155-163	16.2	49
71	The role of insulin pump therapy for type 2 diabetes mellitus. <i>Diabetes/Metabolism Research and Reviews</i> , 2017 , 33, e2822	7.5	13
70	Pharmacological management of nonalcoholic fatty liver disease in type 2 diabetes. <i>Expert Review of Clinical Pharmacology</i> , 2017 , 10, 535-547	3.8	13
69	Hypoglycaemia manifestations and recurrent events: Lessons from the SAVOR-TIMI 53 outcome study. <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 1045-1050	6.7	4
68	Response to Comment on Cefalu et al. Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care EditorsSExpert Forum. <i>Diabetes Care</i> 2016;39:1186-1201. <i>Diabetes Care</i> , 2017 , 40, e23-e24	14.6	1

67	Health-related quality-of-life implications of cardiovascular events in individuals with type 2 diabetes mellitus: A subanalysis from the Saxagliptin Assessment of Vascular Outcomes Recorded in Patients with Diabetes Mellitus (SAVOR)-TIMI 53 trial. <i>Diabetes Research and Clinical Practice</i> , 2017 , 130, 24-33	7.4	14
66	Influences of Breakfast on Clock Gene Expression and Postprandial Glycemia in Healthy Individuals and Individuals With Diabetes: A Randomized Clinical Trial. <i>Diabetes Care</i> , 2017 , 40, 1573-1579	14.6	70
65	Effect of Saxagliptin on Renal Outcomes in the SAVOR-TIMI 53 Trial. <i>Diabetes Care</i> , 2017 , 40, 69-76	14.6	162
64	Combined Analysis of Three Large Interventional Trials With Gliptins Indicates Increased Incidence of Acute Pancreatitis in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2017 , 40, 284-286	14.6	72
63	Update and Next Steps for Real-World Translation of Interventions for Type 2 Diabetes Prevention: Reflections From a Diabetes Care EditorsSExpert Forum. <i>Diabetes Care</i> , 2016 , 39, 1186-201	14.6	86
62	Treatment of Type 2 Diabetes: From "Guidelines" to "Position Statements" and Back: Recommendations of the Israel National Diabetes Council. <i>Diabetes Care</i> , 2016 , 39 Suppl 2, S146-53	14.6	17
61	Introduction to the 5th World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy). <i>Diabetes Care</i> , 2016 , 39 Suppl 2, S113-4	14.6	3
60	Is the Use of DPP-4 Inhibitors Associated With an Increased Risk for Heart Failure? Lessons From EXAMINE, SAVOR-TIMI 53, and TECOS. <i>Diabetes Care</i> , 2016 , 39 Suppl 2, S210-8	14.6	17
59	An update on DPP-4 inhibitors in the management of type 2 diabetes. <i>Expert Opinion on Emerging Drugs</i> , 2016 , 21, 409-419	3.7	36
58	Saxagliptin for the treatment of diabetes - a focus on safety. <i>Expert Opinion on Drug Safety</i> , 2016 , 15, 697-707	4.1	6
57	Cardiovascular Outcomes of Patients in SAVOR-TIMI 53 by Baseline Hemoglobin A1c. <i>American Journal of Medicine</i> , 2016 , 129, 340.e1-8	2.4	27
56	Upregulation of Mitochondrial Content in Cytochrome c Oxidase Deficient Fibroblasts. <i>PLoS ONE</i> , 2016 , 11, e0165417	3.7	16
55	Comment on Shahraz et al. Do Patient Characteristics Impact Decisions by Clinicians on Hemoglobin A1c Targets? <i>Diabetes Care</i> 2016;38:e145-e146. <i>Diabetes Care</i> , 2016 , 39, e227	14.6	1
54	Predisposing Factors for Any and Major Hypoglycemia With Saxagliptin Versus Placebo and Overall: Analysis From the SAVOR-TIMI 53 Trial. <i>Diabetes Care</i> , 2016 , 39, 1329-37	14.6	11
53	Outcome studies and safety as guide for decision making in treating patients with type 2 diabetes. <i>Reviews in Endocrine and Metabolic Disorders</i> , 2016 , 17, 117-27	10.5	3
52	Prognostic Implications of Biomarker Assessments in Patients With Type 2 Diabetes at High Cardiovascular Risk: A Secondary Analysis of a Randomized Clinical Trial. <i>JAMA Cardiology</i> , 2016 , 1, 989-998	16.2	59
51	Improved Insulin Pharmacokinetics Using a Novel Microneedle Device for Intradermal Delivery in Patients with Type 2 Diabetes. <i>Diabetes Technology and Therapeutics</i> , 2016 , 18, 525-31	8.1	34
50	Proposing a new design for self-monitoring blood glucose logs. <i>Diabetes/Metabolism Research and Reviews</i> , 2016 , 32, 60-2	7.5	

49	Evaluation of long-term treatment effect in a type 1 diabetes intervention trial: differences after stimulation with glucagon or a mixed meal. <i>Diabetes Care</i> 2014;37:1384-1391. DOI: 10.2337/dc13-1392. <i>Diabetes Care</i> , 2015 , 38, 179	14.6	
48	Treatment of recent-onset type 1 diabetic patients with DiaPep277: results of a double-blind, placebo-controlled, randomized phase 3 trial. <i>Diabetes Care</i> 2014;37:1392-1400. DOI: 10.2337/dc13-1391. <i>Diabetes Care</i> , 2015 , 38, 178	14.6	5
47	The addition of E (Empowerment and Economics) to the ABCD algorithm in diabetes care. <i>Journal of Diabetes and Its Complications</i> , 2015 , 29, 599-606	3.2	15
46	Efficacy and safety of saxagliptin in older participants in the SAVOR-TIMI 53 trial. <i>Diabetes Care</i> , 2015 , 38, 1145-53	14.6	61
45	Incidence of Fractures in Patients With Type 2 Diabetes in the SAVOR-TIMI 53 Trial. <i>Diabetes Care</i> , 2015 , 38, 2142-50	14.6	46
44	Clinical Assessment of Individualized Glycemic Goals in Patients With Type 2 Diabetes: Formulation of an Algorithm Based on a Survey Among Leading Worldwide Diabetologists. <i>Diabetes Care</i> , 2015 , 38, 2293-300	14.6	35
43	Response to Letter Regarding Article, "Heart Failure, Saxagliptin and Diabetes Mellitus: Observations From the SAVOR-TIMI 53 Randomized Trial". <i>Circulation</i> , 2015 , 132, e121-2	16.7	45
42	Improved Postprandial Glucose Control Using the InsuPad Device in Insulin-Treated Type 2 Diabetes: Injection Site Warming to Improve Glycemic Control. <i>Journal of Diabetes Science and Technology</i> , 2015 , 9, 639-43	4.1	4
41	Type 2 diabetes mellitus. <i>Nature Reviews Disease Primers</i> , 2015 , 1, 15019	51.1	651
40	Antidiabetic Effect of Interleukin-1 β Antibody Therapy Through β Cell Protection in the Cohen Diabetes-Sensitive Rat. <i>Diabetes</i> , 2015 , 64, 1780-5	0.9	10
39	Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes and moderate or severe renal impairment: observations from the SAVOR-TIMI 53 Trial. <i>Diabetes Care</i> , 2015 , 38, 696-705	14.6	114
38	Improved pharmacokinetic and pharmacodynamic profiles of insulin analogues using InsuPatch, a local heating device. <i>Diabetes/Metabolism Research and Reviews</i> , 2014 , 30, 686-92	7.5	7
37	Beyond metformin: safety considerations in the decision-making process for selecting a second medication for type 2 diabetes management: reflections from a diabetes care editors' expert forum. <i>Diabetes Care</i> , 2014 , 37, 2647-59	14.6	48
36	Treatment of recent-onset type 1 diabetic patients with DiaPep277: results of a double-blind, placebo-controlled, randomized phase 3 trial. <i>Diabetes Care</i> , 2014 , 37, 1392-400	14.6	43
35	Evaluation of long-term treatment effect in a type 1 diabetes intervention trial: differences after stimulation with glucagon or a mixed meal. <i>Diabetes Care</i> , 2014 , 37, 1384-91	14.6	10
34	Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial. <i>Circulation</i> , 2014 , 130, 1579-88	16.7	479
33	Insulin therapy in people with type 2 diabetes: opportunities and challenges?. <i>Diabetes Care</i> , 2014 , 37, 1499-508	14.6	94
32	Response to comment on Home et al. Insulin therapy in people with type 2 diabetes: opportunities and challenges? <i>Diabetes care</i> 2014;37:1499-1508. <i>Diabetes Care</i> , 2014 , 37, e247	14.6	1

31	Incidence of pancreatitis and pancreatic cancer in a randomized controlled multicenter trial (SAVOR-TIMI 53) of the dipeptidyl peptidase-4 inhibitor saxagliptin. <i>Diabetes Care</i> , 2014 , 37, 2435-41	14.6	55
30	Guideline approach to therapy in patients with newly diagnosed type 2 diabetes. <i>Diabetes Care</i> , 2013 , 36 Suppl 2, S139-44	14.6	42
29	Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. <i>New England Journal of Medicine</i> , 2013 , 369, 1317-26	59.2	2459
28	Personalized management of hyperglycemia in type 2 diabetes: reflections from a Diabetes Care Editors' Expert Forum. <i>Diabetes Care</i> , 2013 , 36, 1779-88	14.6	114
27	Emerging gliptins for type 2 diabetes. <i>Expert Opinion on Emerging Drugs</i> , 2013 , 18, 245-58	3.7	24
26	Dietary copper supplementation restores β cell function of Cohen diabetic rats: a link between mitochondrial function and glucose-stimulated insulin secretion. <i>American Journal of Physiology - Endocrinology and Metabolism</i> , 2013 , 304, E1023-34	6	20
25	Early insulinization to prevent diabetes progression. <i>Diabetes Care</i> , 2013 , 36 Suppl 2, S190-7	14.6	22
24	Rational therapy for diabetes: early recognition of adverse effects and avoidance of disruptive false alarms. <i>Diabetes/Metabolism Research and Reviews</i> , 2012 , 28, 321-4	7.5	11
23	Efficacy and safety of taspoglutide monotherapy in drug-naive type 2 diabetic patients after 24 weeks of treatment: results of a randomized, double-blind, placebo-controlled phase 3 study (T-emerge 1). <i>Diabetes Care</i> , 2012 , 35, 485-7	14.6	29
22	Post hoc subgroup analysis of the HEART2D trial demonstrates lower cardiovascular risk in older patients targeting postprandial versus fasting/premeal glycemia. <i>Diabetes Care</i> , 2011 , 34, 1511-3	14.6	64
21	The design and rationale of the saxagliptin assessment of vascular outcomes recorded in patients with diabetes mellitus-thrombolysis in myocardial infarction (SAVOR-TIMI) 53 study. <i>American Heart Journal</i> , 2011 , 162, 818-825.e6	4.9	92
20	Impact of the U.S. Food and Drug Administration cardiovascular assessment requirements on the development of novel antidiabetes drugs. <i>Diabetes Care</i> , 2011 , 34 Suppl 2, S101-6	14.6	58
19	The continuing need for drug development and clinical trials in type 2 diabetes and its complications: introduction to the RDS special issue. <i>Review of Diabetic Studies</i> , 2011 , 8, 288-92	3.6	1
18	The A1C and ABCD of glycaemia management in type 2 diabetes: a physician's personalized approach. <i>Diabetes/Metabolism Research and Reviews</i> , 2010 , 26, 239-44	7.5	90
17	Introduction to the Second World Congress on Controversies to Consensus in Diabetes, Obesity and Hypertension (CODHy): dilemmas in clinical practice. <i>Diabetes Care</i> , 2009 , 32 Suppl 2, S149-50	14.6	1
16	Effect of a local heating device on insulin and glucose pharmacokinetic profiles in an open-label, randomized, two-period, one-way crossover study in patients with type 1 diabetes using continuous subcutaneous insulin infusion. <i>Clinical Therapeutics</i> , 2009 , 31, 980-7	3.5	44
15	Challenges in developing endpoints for type 1 diabetes intervention studies. <i>Diabetes/Metabolism Research and Reviews</i> , 2009 , 25, 694-704	7.5	12
14	Managing labor and delivery of the diabetic mother. <i>Expert Review of Obstetrics and Gynecology</i> , 2009 , 4, 547-554		3

13	Effects of prandial versus fasting glycemia on cardiovascular outcomes in type 2 diabetes: the HEART2D trial. <i>Diabetes Care</i> , 2009 , 32, 381-6	14.6	281
12	Efficacy and safety of sitagliptin added to ongoing metformin therapy in patients with type 2 diabetes. <i>Current Medical Research and Opinion</i> , 2008 , 24, 537-50	2.5	206
11	DiaPep277 preserves endogenous insulin production by immunomodulation in type 1 diabetes. <i>Annals of the New York Academy of Sciences</i> , 2006 , 1079, 340-4	6.5	18
10	Efficacy and safety of biphasic insulin aspart 30 combined with pioglitazone in type 2 diabetes poorly controlled on glibenclamide (glyburide) monotherapy or combination therapy: an 18-week, randomized, open-label study. <i>Clinical Therapeutics</i> , 2005 , 27, 1432-43	3.5	27
9	Immune modulation for prevention of type 1 diabetes mellitus. <i>Trends in Biotechnology</i> , 2005 , 23, 128-34	15.1	38
8	Diabetes: insulin resistance and derangements in lipid metabolism. Cure through intervention in fat transport and storage. <i>Diabetes/Metabolism Research and Reviews</i> , 2005 , 21, 3-14	7.5	138
7	Addition of biphasic insulin aspart 30 to rosiglitazone in type 2 diabetes mellitus that is poorly controlled with glibenclamide monotherapy. <i>Clinical Therapeutics</i> , 2003 , 25, 3109-23	3.5	19
6	Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. <i>Lancet, The</i> , 2001 , 358, 1749-53	4.0	44.0
5	Rapid activation of glycogen synthase and protein phosphatase in human skeletal muscle after isometric contraction requires an intact circulation. <i>Pflugers Archiv European Journal of Physiology</i> , 1995 , 431, 259-65	4.6	13
4	Effects of human diabetic serum on the in vitro development of early somite rat embryos. <i>Teratology</i> , 1989 , 39, 85-92		20
3	Pharmacokinetic analysis of sustained-release dosage forms of theophylline in humans: comparison of single and multiple dose studies. <i>Biopharmaceutics and Drug Disposition</i> , 1987 , 8, 427-35	1.7	7
2	Pharmacokinetics of valproic acid in volunteers after a single dose study. <i>Biopharmaceutics and Drug Disposition</i> , 1985 , 6, 33-42	1.7	13
1	Practical Approach to the Implementation of Diabetes Prevention	195-208	